article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

But what happens when that in-person meeting is no longer a viable option for your prospect? Bearing the brunt of these COVID19 restrictions, pharmaceutical reps have had a hard time getting in the door to make sales, and their employers have noticed: Limited In-Person Access To HCPs.

Pharma 52
article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

If we concentrate on cost, EU governments like to focus on out-of-pocket expenses for costing R&D, for example, the amount of money you pay a contract research organisation to conduct a clinical trial for your product. The actual legislation will then have a certain implementation period and will be prospective, for the most part.